Kentucky’s annual rate of opioid-related fatalities remains one of the highest nationwide. Despite efforts to help those who are struggling with opioid addiction, there is still progress to be made. Contact our opioid addiction treatment center today.
The State of Addiction Treatment in Kentucky
Kentucky’s addiction treatment system is struggling with the limited resources for substance use disorder treatment, which is 10.7% of Kentucky’s annual budget.
According to an article by the NKY Tribune posted in January of 2020, a new Kentucky Health Issues Poll (KHIP) report shows:
- An uptick in prescription pain medicine misuse last year
- A consistent problem with heroin and methamphetamine use
- Nearly two in five Kentucky adults in 2019 said they knew someone who misused prescription pain meds
- About one in five said they knew someone who used meth and heroin
COVID-19 and Addiction
In 2020, the state of Kentucky was near the lower half of the ranking of COVID-19 cases per state. However, this does not mean that Kentucky residents have not been impacted severely. Those who struggle with addiction are at higher risk of complications from COVID-19. Additionally, the isolation and stress brought on by the pandemic have been challenging for many.
Fatal overdoses in Lexington have increased at least 42 percent compared to this time last year. The Lexington Herald Leader says that Health and law enforcement officials across more than ten Kentucky counties have reported similar trajectories in their communities related to an increase of overdoses, which remained steady over the past two months, then periodically surging. Prioritizing wrap around services (see bio-psycho-social model) and person-focused care during this time for Kentuckians is essential for getting people back in the workforce and achieving lifelong recovery after COVID-19.
What to Look For in an Addiction Treatment Center in Kentucky
Gone are the days of simply sending people straight into outpatient treatment or inpatient treatment without an end goal in sight. A life with meaning and free from dangerous substances should be the new standard of quality care. Kentuckians, especially those in the hardest-hit areas of Lexington and Louisville, are lacking evidence-based treatment options.
BrightView is offering Kentuckians a different kind of approach to addiction treatment. Instead of methadone, we offer several other medications that are medically proven to help those with dependence on opioid drugs. These medications are considered maintenance medications and are commonly used to treat conditions that are chronic or long-term. BrightView treats addiction with FDA-approved medicines like buprenorphine to help you focus on your recovery. We also prescribe medicines such as naltrexone (Vivitrol) and a combination of buprenorphine and naloxone (Suboxone). In almost all BrightView’s addiction treatment centers, there is an on-site pharmacy, so essentially, a “one stop” shop for patients is available.
Although the procedure to be approved for an on-site pharmacy is often elaborate and complicated, BrightView has already taken the needed steps to advocate for on-site pharmacies for our newest locations in Lexington and Louisville. In the meantime, in Kentucky, BrightView will work closely with local businesses to ensure that each patient has a designated pharmacy to place, fill, and pick up a prescription.
Reach Out to BrightView Today
Our goal at BrightView is to provide drug abuse treatment options that will help someone achieve long-term recovery. In addition to addiction medicine, our participants’ treatment plans focus on their overall mental health. BrightView incorporates both individual and group therapy in our treatment services so that patients can address the challenges that come along with the disease of addiction. If you or someone you love is struggling with substance abuse, we encourage you to contact us today. Our friendly and caring recovery center staff answer the phones 24 hours a day. Connect with us at 888.501.9865 or reach out online to learn more.